ArticleScientific reports2026
Astaxanthin effect on tissue transglutaminase expression in human neuronal differentiated stem cells exposed to hypoxia and hypoxia/reoxygenation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Astaxanthin represents a natural antioxidant compound extracted from marine organisms, showing neuroprotective effects. In this study, for the first time, we highlighted the effect of astaxanthin pre-treatment on localization and expression of tissue transglutaminase isoforms (TG2-L and TG2-S) in human Neuronal Cells Differentiated from Human Dental Pulp Stem Cells (hNCs) exposed to hypoxia and/or hypoxia/reoxygenation. The percentage of cell viability, mitochondrial membrane potential and caspase-3 cleavage were evaluated. In particular, TG2 is involved in hypoxia diseases, playing different roles on the basis of its localization and conformation state. Our results highlight a significant increase of isoforms levels in hypoxia and/or hypoxia/reoxygenation, compared with the normoxia condition. In hypoxia and/or hypoxia/reoxygenation a significant decrease of the percentage of cell viability, an alteration mitochondrial membrane potential and the activation of the apoptotic pathway were observed. Astaxanthin pre-treatment was able to counteract the excitotoxic effect induced by hypoxia and/or hypoxia/reoxygenation, restoring TG2 isoform levels, the percentage of cell viability and the mitochondrial membrane potential to normoxia condition, inhibiting also apoptotic pathway activation. Our data highlight that astaxanthin could represent a candidate adjuvant for neural regeneration under hypoxic conditions, acting on the TG2 state, which plays a key role in apoptosis and self-renewal capacity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.